#ESMO20: VBI Vaccines announces additional biomarker data from the ongoing Phase 1/2a study evaluating VBI-1901, the company’s cancer vaccine immunotherapeutic candidate in recurrent glioblastoma (GBM) patients. Learn more about the data and e-poster presented at the ESMO - European Society for Medical Oncology Virtual Congress 2020: https://bit.ly/3hFoCtM #VBIV
VBI Vaccines will present data on the company’s cancer vaccine immunotherapeutic candidate in recurrent glioblastoma (GBM) at ESMO - European Society for Medical Oncology Virtual Congress 2020. The e-poster, available September 17-21, will highlight additional biomarker data from candidate VBI-1901. Learn more about the presentation and Phase 1/2a study design: https://bit.ly/35BoSrw #ESMO20 #VBIV
This week, our CEO, Jeff Baxter, was interviewed on Invest Ottawa's “Invested in our New Reality” podcast. Jeff chatted with host Shavonne Hasfal-McIntosh about #COVID19 vaccine development, our coronavirus program, and how vaccine companies are working together in unprecedented ways: https://apple.co/3k8VPQ2 #VBIV
VBI Vaccines delivered two presentations at EASL's The Digital International Liver Congress 2020 virtual meeting. The presentations featured data from our Phase 3 program evaluating Sci-B-Vac®, the company’s tri-antigenic prophylactic hepatitis B vaccine. To learn more, please follow the press release link: https://bit.ly/3jsMkuA #VBIV
“Many scientists see their ongoing vaccine work as part of a long game — one that the well-being of entire nations will depend on.”
Thank you Carl Zimmer & The New York Times for highlighting our work. #VBIV is proud to be part of the #COVID19 effort. https://nyti.ms/2G0SBiB
NYTIMES.COM
What if the First Coronavirus Vaccines Aren’t the Best?
#Breaking: VBI Vaccines announces preclinical data from its #coronavirus program and selects two vaccine candidates to advance into adaptive Phase 1/2 clinical study, pending regulatory approval. Click to read more: https://bit.ly/3gDo2wh #VBIV
Our management team will discuss #VBIV's vaccine immunotherapeutic candidate for chronic #hepatitisB at the H.C. Wainwright HBV Mini-Conference. CEO Jeff Baxter & CSO Dave Anderson will participate in a fireside chat on October 20. Read more: https://bit.ly/342ElzD
This morning, VBI Vaccines announced third quarter 2020 financial results, recent pipeline program highlights, and upcoming milestones. Read more here: https://bit.ly/3jRn80H #VBIV
VBI Vaccines delivered two e-poster presentations at #IDWeek2020 featuring data from our Phase 3 clinical program evaluating Sci-B-Vac®, our 3-antigen prophylactic hepatitis B vaccine. View the e-posters and learn more about the data here: https://bit.ly/3osyU58 #VBIV #hepatitisB
VBI Vaccines announced today the European Medicines Agency (EMA) approval of our Marketing Authorization Application (MAA) for our 3-antigen prophylactic hepatitis B vaccine candidate, which initiates the EMA’s regulatory review process. We are seeking approval for the prevention of infection caused by all known subtypes of the hepatitis B virus in adults. Learn more about VBI’s 3-antigen #HBV vaccine: https://bit.ly/3rq4yll #VBIV
In case you missed it: Our partner, Brii Biosciences, has announced that preparations are underway for a Phase 2 study to assess our HBV immunotherapeutic candidate, VBI-2601 (BRII-179), in combination with BRII-835 (VIR-2218), a novel RNAi therapeutic designed to inhibit expression of all HBV proteins, as a potential functional cure for chronic hepatitis B infection. The study is expected to initiate in Q1 2021. Read more here: https://bit.ly/2Wux0UF
BRIIBIO.COM
Brii Biosciences - Breakthrough innovation & insight
In case you missed it, members of VBI’s leadership team are set to discuss recent news and strategic outlook for its hepatitis B portfolio with covering analyst, Steven Seedhouse, Ph.D., during a fireside chat at 11:00AM ET today. Register and watch the event here: https://bit.ly/36T79vN #VBIV #HBV
Today, VBI Vaccines announced the company’s commercialization partnership with Syneos Health for VBI’s 3-antigen hepatitis B vaccine. Learn more: https://bit.ly/37EEfyM #VBIV
Members of the VBI leadership team will be discussing recent news and strategic outlook for the Company’s hepatitis B portfolio with covering analyst, Steven Seedhouse, Ph.D., from Raymond James & Associates, Inc. during a fireside chat at 11:00 AM ET on December 8. Learn more and register to the event here: https://bit.ly/33Bji6F #VBIV #HBV
VBI Vaccines announced today the submission of a Biologics License Application to the U.S. Food and Drug Administration (FDA) seeking approval of the Company’s 3-antigen prophylactic hepatitis B vaccine candidate, for the prevention of infection caused by all known subtypes of the hepatitis B virus in adults. Learn more about the BLA submission: https://bit.ly/3o7Jw8k #VBIV #HBV